TILRR, a Novel IL-1RI Co-receptor, Potentiates MyD88 Recruitment to Control Ras-dependent Amplification of NF-kappa B by Zhang, X. et al.
This is a repository copy of TILRR, a Novel IL-1RI Co-receptor, Potentiates MyD88 
Recruitment to Control Ras-dependent Amplification of NF-kappa B.
White Rose Research Online URL for this paper:
http://eprints.whiterose.ac.uk/165497/
Version: Published Version
Article:
Zhang, X., Shephard, F., Kim, H.B. et al. (6 more authors) (2010) TILRR, a Novel IL-1RI 
Co-receptor, Potentiates MyD88 Recruitment to Control Ras-dependent Amplification of 
NF-kappa B. Journal of Biological Chemistry, 285 (10). pp. 7222-7232. ISSN 0021-9258 
https://doi.org/10.1074/jbc.M109.073429
© 2010 by The American Society for Biochemistry and Molecular Biology, Inc. Creative 
Commons Attribution Non-Commercial License applies to this article 
(http://creativecommons.org/licenses/by-nc/3.0/).
eprints@whiterose.ac.uk
https://eprints.whiterose.ac.uk/
Reuse 
This article is distributed under the terms of the Creative Commons Attribution-NonCommercial (CC BY-NC) 
licence. This licence allows you to remix, tweak, and build upon this work non-commercially, and any new 
works must also acknowledge the authors and be non-commercial. You don’t have to license any derivative 
works on the same terms. More information and the full terms of the licence here: 
https://creativecommons.org/licenses/ 
Takedown 
If you consider content in White Rose Research Online to be in breach of UK law, please notify us by 
emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request. 
TILRR, a Novel IL-1RI Co-receptor, Potentiates MyD88
Recruitment to Control Ras-dependent Amplification of NF-B*□S
Received for publication, October 9, 2009, and in revised form, November 16, 2009 Published, JBC Papers in Press, November 25, 2009, DOI 10.1074/jbc.M109.073429
Xiao Zhang‡, Freya Shephard‡, Hong B. Kim‡, Ian R. Palmer‡, Selina McHarg‡, Gregory J. S. Fowler‡,
Luke A. J. O’Neill§, Endre Kiss-Toth¶, and Eva E. Qwarnstrom‡1
From the Units of ‡Cell Biology and ¶Cardiovascular Research, School of Medicine and Biomedical Sciences, University of Sheffield,
Sheffield S102RX, United Kingdom, the §School of Biochemistry and Immunology, Trinity College, Dublin 2, Ireland, and the
Affiliated Department of Pathology, University of Washington, Seattle, Washington 98195-7470
Host defense against infection is induced by Toll-like and
interleukin (IL)-1 receptors, and controlled by the transcrip-
tion factor NF-B. Our earlier studies have shown that IL-1
activation impacts cytoskeletal structure and that IL-1 recep-
tor (IL-1RI) function is substrate-dependent. Here we iden-
tify a novel regulatory component, TILRR, which amplifies
activation of IL-1RI and coordinates IL-1-induced control
with mechanotransduction. We show that TILRR is a highly
conserved and widely expressed enhancer of IL-1-regulated
inflammatory responses and, further, that it is a membrane-
bound glycosylated protein with sequence homology tomem-
bers of the FRAS-1 family. We demonstrate that TILRR is
recruited to the IL-1 receptor complex and magnifies signal
amplification by increasing receptor expression and ligand
binding. In addition, we show that the consequent potentiation
of NF-B is controlled through IL-1RI-associated signaling
components in coordination with activation of the Ras GTPase.
Using mutagenesis, we demonstrate that TILRR function is
dependent on associationwith its signaling partner and, further,
that formation of the TILRR-containing IL-1RI complex
imparts enhanced association of the MyD88 adapter during
ligand-induced activation of NF-B.We conclude that TILRR is
an IL-1RI co-receptor, which associates with the signaling
receptor complex to enhance recruitment ofMyD88andcontrol
Ras-dependent amplification of NF-B and inflammatory
responses.
Immune and inflammatory response are regulated by Toll-
like and IL-12 receptors (1–4). Their activation is initiated by
ligand binding and co-receptor association to the receptor
complex, followed by recruitment of distinct sets of adapter
proteins to the cytoplasmic Toll/IL-1 receptor domain, com-
mon to all members of the family.
The IL-1 receptor subfamily is a continuously growing group
of regulatory proteins, named after the initially identified type I
signaling receptor (IL-1RI) (5, 6). Its activation is regulated by the
proinflammatory cytokines IL-1 and IL-1 and the receptor
antagonist, IL-1ra, and by association of the IL-1R accessory pro-
tein (AcP) with the receptor complex (6). IL-1 responses are, in
addition, linked to events related to cell attachment and the
cytoskeleton and controlled by the small GTPases (7, 8). Receptor
activation, followedby recruitment of theMyD88 adapter and by
association of the receptor-associated kinases (IRAKs) and
TRAF6, leads to induction of the mitogen-activated protein
kinase cascade and the NF-B pathway (1–3, 9, 10).
The importance of receptor complex composition and stoi-
chiometry in adapter protein recruitment and TIR signaling is
well recognized (4, 11–13). Our earlier studies have identified a
cell surface heparan sulfate proteoglycan, which is recruited to
the IL-1RI complex in a substrate-dependent manner (14, 15).
Here we report on the cloning and characterization of this
novel co-receptor, TILRR (Toll-like/IL-1 receptor regulator).
We show that TILRR associates with the extracellular domain
of IL-1RI and magnifies NF-B-regulated inflammatory
responses by potentiating recruitment of MyD88 and linking
TIR activation with mechanotransduction by controlling
induction of the Ras GTPase.
EXPERIMENTAL PROCEDURES
Tissue Culture—Murine and human cell lines and primary
cells were cultured under conventional conditions. HeLa cells,
endothelial cells (HMEC-1, CDC, Ades, Lawley, and Candal),
fibroblasts (NIH 3T3 and primary human gingival fibroblasts,
HGF), monocytes (THP1, J774, BL413, ML-1, HL-60, U937,
MOLT4, and K562), macrophages (Raw 264.7), embryonic kid-
ney (HEK293), mouse epithelial cells (IL-1RI-transformed
C127 cells), and primary human peripheral bloodmononuclear
cells (PBMCs) were cultured at 37 °C and 5% CO2 in DMEM
(Invitrogen) with 10% fetal calf serum (Invitrogen or Cambrex),
penicillin (50 units/ml), and streptomycin (50 g/ml) (Invitro-
gen) or in MCDB 131 (Invitrogen) with 10% fetal calf serum,
epidermal growth factor (10 ng/ml), hydrocortisone (1 g/ml),
and L-glutamine (2 mM) (all from Sigma) and the C127, in addi-
tion, with G418 (500 g/ml). Cells were detached in EDTA (5
mM, Sigma) and plated on bare plastic or on fibronectin (10
g/ml; Sigma) to enhance levels of endogenous TILRR (lucifer-
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ase assays, 96-well plates (6.0  103 cells/well); confocal
microscopy, 8-well chamber slides (12.0  103 cells/well);
Western analysis, 24-well plates (35  103 cells/well); enzyme-
linked immunosorbent assays, 6-well plates (2 105 cells/well);
radioreceptor assays and immunoprecipitation, 10-cm dishes
(1.0 106 cells)) and stimulatedwith IL-1 (1 nM) (a kind gift of
Dr. Steve Pool (National Institute for Biological Standards
and Control)), TNF (10 ng/ml) (Promega), PDGFBB (25
ng/ml) (R&D Systems), or TGF-2 (3 ng/ml) (R&D Systems)
24–48 h after transfection.
Protein Identification—In-gel digestion and MALDI-TOF
was carried out as previously (16), and data were analyzed by
Profound,MASCOT,MOWSE, and PeptIdent. Sequence anal-
ysis and alignments used PROSITE, ClustalW, and Lasergene
(DNAStar).
cDNA Constructs—cDNA clones of human TILRR (GenBankTM
number BC031064) were generated in pBluescript (Geneser-
viceMGCClone 33379), pcDNA3.1 (Invitrogen), and pMONO
(Invivogen) and expressed as EGFP fusion proteins (N- or
C-terminal) usingGateway cloning vectors (Invitrogen). Con-
structs containing IBEGFP, IL-1RI chimera, DNMyD88,
N17Ras, DDIRAK-1, DNTRAF6, the IL-8 promoter (IL-8luc
and IL-8EGFP), TNF receptor (Invivogen), platelet-derived
growth factor receptor, or TGFR2 (Invitrogen) were used as
described (8, 17–20).
siRNAConstructs—Multiple siRNAs weremade against the
mouse and human TILRR sequence. siRNA constructs were
made against the TILRR mouse sequence, targeting regions
separated by 230 base pairs (5-CUCUCUCCACAGGUCU-
UUGTT-3 (sense)/5-CAAAGACCUGUGGAGAGAGTT-
3 (antisense) and 5-CCAGACUGUAACAUCAUCCTT-3
(sense)/5-GGAUGAUGUUACAGUCUGGTT-3 (antisense))
(Eurogentec) and verified by RT-PCR and Western analysis.
Similarly, constructs against human TILRR, specifically
designed to target a unique TILRR sequence at the 5-untrans-
lated region, were synthesized (Dharmacon) (5-CUGGCACU-
CACUCAAGCUUUU-3 (sense)/5-PAAGCUUGAGUGAG-
UGCCAGUU-3 (antisense) and 5-AUUAGAUAUUCAAG-
AUGGCUU-3 (sense)/5-PGCCAUCUUGAAUAUCUAA-
UUU-3 (antisense)) and were verified by RT-PCR and
Western analysis. Scrambled siRNA (5-GUUAACGAUGAU-
CGAUAAUTT-3 (sense)/5-AUUAUCGAUCAUCGUUAA-
CTT-3 (antisense)) (Qiagen) or random siRNAwith no genomic
equivalent (Eurogentec),whichdemonstratednomore thana10%
reduction in IL-1-induced activity, were used as controls.
Transfections—Cells were transfected by conventional
methods, including using calcium phosphate (19) or Jetsi
(Eurogentec) or Nucleofect (Amaxa). Constant levels of
cDNA were obtained by adding relevant amounts of empty
vector. Controls included cultures transfected with appro-
priate amounts of empty vector alone. Similarly, experiments
using TILRR siRNA included controls with relevant levels of
random or scrambled siRNA. Transfection levels were assessed
in parallel cultures by using an EGFP-containing control vector
and microscopy.
Luciferase Assay—Activity was determined using the Dual-
Luciferase reporter assay system (Promega).
RNA Extraction—Total RNA was extracted from various
cells using the RNEasy kit (Qiagen).
First Strand cDNA Synthesis—First strand cDNA synthesis
was performed using a high capacity cDNAarchive kit (Applied
Biosystems).
RT-PCR—RT-PCR used first strand cDNA as template with
TILRR-specific primers (5-agagccctgcctgtggtaac-3 (forward)/
5-gaaggggaatgcaagagtgtgata-3 (reverse)) or primers for glyc-
eraldehyde-3-phosphate dehydrogenase (5-aactttggtatcgtgga-
aggac-3 (forward)/5-tggtcgttgagggcaatg-3 (reverse)).
Quantitative RT-PCR—Quantitative RT-PCR used first
strand cDNA as template with TILRR-specific primers/
probe and glyceraldehyde-3-phosphate dehydrogenase prim-
ers/probe or actin primers/probe (Sigma) and 2 Mastermix
(Eurogentec). Experiments included non-RT and water-only
controls, neither of which produced a detectable signal.
Mutagenesis—Mutations were introduced in the TILRR
core protein and in the extracellular domain of IL-1RI
through alanine substitutions at sites selected based on sec-
ondary structure predictions (Lasergene Software; Garnier-
Robson prediction) and using the QuikChange II mutagen-
esis kit (Stratagene). Similarly, alanine substitutions of serine
residues were introduced at predicted GAG attachment sites
(112 and 417) within the TILRR core protein. Mutations of the
IL-1RI-TIR domain were introduced as previously (17). All
sequences were confirmed by PCR andWestern analysis, func-
tionality was tested by luciferase assays, and cell surface expres-
sion of wild type receptors and of IL-1RI and TILRR mutants
was confirmed by fluorescence-activated cell sorting analysis.
Protein Extraction—Cells were harvested as described (14),
using EDTA (5 mM), and extracted by resuspending (50 l/106
cells) in radioimmuneprecipitation buffer (SantaCruzBiotech-
nology, Inc., Santa Cruz, CA) or in extraction buffer (1% Triton
X-100), containing 2 mM phenylmethylsulfonyl fluoride, 1 M
pepstatin, 1 M leupeptin, and incubated on ice (15 min), and
DNA was sheared by passages through a hypodermic needle.
Following centrifugation (13,000 rpm, 4 °C), supernatant was
mixed with an equal volume of 2 sample buffer (0.1 M Tris-
HCl) and denatured (95 °C, 5 min).
Immunoprecipitation—Cross-linked samples were extracted
using radioimmune precipitation buffer or Triton X-100-con-
taining extraction buffer, as above, total protein was deter-
mined, and equal amounts were immunoprecipitated, using an
anti-IL-1RI antibody (2 g/ml; Santa Cruz Biotechnology, Inc.)
andproteinG-Sepharosebeads (50l/ml, 4 °C,overnight) (Sigma)
or Protein A/G-agarose beads (20 l/ml, 4 °C, overnight; Santa
Cruz Biotechnology, Inc.), as described (14). Controls included
precipitations in the absence of the primary antibody.
Western Analysis—Samples were resolved on SDS-PAGE (4,
6, 8, or 4–12%) and transferred to polyvinylidene difluoride,
using conventional procedures. TILRR was detected by rabbit
polyclonal anti-TILRR (1:1000, custom Eurogentec). Incuba-
tion with the antibody and treatment as outlined below identi-
fied the functional endogenous TILRR at 70 kDa, demonstrated
its reduction by the TILRR-specific siRNA, and recognized the
exogenous TILRR, induced by the TILRR cDNA. The only
other band observedwas significantlyweaker, corresponding to
the non-functional variant at 40 kDa (data not shown). Simi-
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larly, IL-1RI, MyD88, and -actin were detected using anti-IL-
1RI (1:1000), anti-MyD88 (1:1000), and anti--actin (1:1000 or
1:2000, loading control), respectively (Santa Cruz Biotechnol-
ogy). Incubation with a relevant horseradish peroxidase-conju-
gated secondary antibody (1:5000; Santa Cruz Biotechnology)
was followed by ECL visualization. Controls included incuba-
tion with secondary antibody alone. Analysis of immunopre-
cipitated samples, in addition, used IgG as a loading control.
Phalloidin Staining—Cells transfected with a mock construct,
TILRR cDNA, or N17Ras or TILRR siRNA were incubated with
IL-1 (1 nM, 1 h) or medium alone (control), fixed (paraformal-
dehyde, 3.7%, room temperature), permeabilized (0.1% Triton
X-100, 20 °C), stained with rhodamine-tagged phalloidin (20
min, room temperature; Invitrogen), and analyzed by confocal
microscopy.
FACS Analysis—Cells were transfected with a mock con-
struct (10 g/1  106 cells) or wild type or mutant IL-1RI con-
struct (12 g/1  106 cells) or wild type or mutant TILRR
construct (10 g/1  106 cells). Twenty-four hours after trans-
fection, cells were fixed (2% paraformaldehyde, 15 min, 4 °C)
and incubated with primary anti-IL-1RI (4g/ml, 40min, 4 °C)
or anti-TILRR (4.5 g/ml, 40 min, 4 °C) or with normal rabbit
IgG (control) and with fluorescein isothiocyanate-conjugated
anti-rabbit antibody (10 g/ml, 40 min, 4 °C) and analyzed by
FACS.
Protein Quantitation—Total protein extracts were quanti-
tated using the BCA assay (Pierce).
Enzyme-linked Immunosorbent Assay—IL-6 protein levels
were measured by ELISA Ready-SET-Go! (eBioscience).
Single Cell Analysis—Cells transfectedwith IB-EGFPwere
stimulated with IL-1 (1 nM, 60 min), and levels of the fusion
protein were determined by continuous monitoring by confo-
cal microscopy, as described (19).
IL-1 Binding—IL-1 was radiolabeled using Chloramine-T,
and cells were incubated with 125I-IL-1, as described (14), and
used in radioreceptor assays, and nonspecific binding was
determined by incubation in the presence of a 100-fold excess
cold ligand, subtracted from the data. In addition, incubated
cells were extracted and separated by SDS-PAGE, and dried
gels were allowed to expose films, as described (14).
Cross-linking—Cells were incubated with amine-directed
bis(sulfosuccinimidyl)suberate (membrane-impermeable, 5
mM, 2 h, 4 °C) or DSS (membrane-permeable, 5 mM, 30 min,
room temperature) (Pierce), as described (14).
Ras Activation—Ras activation was determined using the
EZ-DetectTM Ras activation kit (Pierce). HeLa cells were trans-
fected, as above, and after 24 h were stimulated with IL-1 (1
nM). Active Ras was immunoprecipitated, using the Ras-bind-
ing domain of Raf 1 fused toGST, and detected byWestern blot
analysis using an anti-Ras antibody.
Statistical Analysis—p values were calculated using
GraphPad Prism.
RESULTS
TILRR Is a Unique, Widely Expressed Protein, Which Con-
trols IL-1RI-induced Inflammatory Responses—TILRR was
detected because of its substrate-dependent association with
IL-1RI (14), and identified through peptide mapping based
on MALDI-TOF (Fig. 1A). Data base searching, using the
obtained sequences DVDSGGVAYQHSGGGAR, VAELPLA-
DKVESTTDLHFLR, and TGHWEWIGGEPVAFTNWR iden-
tified a gene present in humans (GenBankTM number BC031064)
andmice (GenBankTMnumberAK052415.1), whichmapped to
human chromosome 9, location 9p22.3. Quantitative RT-PCR
demonstrated expression of TILRR in a wide range of primary
cells and cell lines of lymphocytic and mesenchymal origin
from humans and mice (Fig. 1B). Further, Western analysis
identified a TILRR core protein of 70–80 kDa in the same cell
types (Fig. 1C). Inconsistencies between mRNA and protein
levels, together with slight variations in size, are consistent with
cell type-specific translational or post-translational processing.
Multiple alignments of the TILRR core protein using
ClustalW, revealed significant homology with members of the
FRAS1 family of proteoglycans (21). Specifically, TILRR is a
protein encoded by an alternatively splicedmRNA species from
the highly conserved FREM1 gene (supplemental Fig. S1).
GeneScan predictions and expressed sequence tag analysis sug-
gested that the gene gives rise to multiple alternatively spliced
mRNAs. Subsequent bioinformatics analysis of both the human
andmurine FREM1 locus revealed that other potential variants
would encode for proteins with molecular masses of around 40
kDa, significantly lower than 70–80 kDa determined for
TILRR. In addition, further analysis revealed that these smaller
species would lack the functionally relevant N-terminal GAG
attachment site at residue 112 (supplemental Fig. S2).
Sequence analysis identified two potential start sites up-
stream of the open reading frame, which were both tested in
functional assays. These demonstrated that the most potent
form of TILRR, with a start site at the methionine at residue 7
(marked in Fig. 1A), caused a nearly 7-fold concentration-de-
pendent potentiation of IL-1-induced IL-8 activation (Fig. 2A).
Conversely, increasing concentrations of a TILRR siRNA, dem-
onstrated to inhibit TILRR expression by up to 60–80% (sup-
plemental Fig. S3), resulted in a successive reduction in pro-
moter activation of up to 80%, which, as the cDNA-induced
amplification, affected ligand-controlled levels only. In con-
FIGURE 1. TILRR is a widely expressed protein of 70 – 80 kDa. A, the TILRR core protein sequence. Shown is the amino acid sequence of mouse and human
TILRR protein identified from partial trypsin digests of mouse epithelial cells (C127). Samples were purified by immunoprecipitation and SDS-PAGE and
analyzed by MALDI-TOF and using Profound, MASCOT, MOWSE, and PeptIdent. *, methionine at residue 7. B, TILRR mRNA is expressed in a variety of cell lines.
RNA extracted from various cell lines and primary human periferal mononuclear cells (PBMC 1 and 2), was used to synthesize a first strand cDNA. TILRR and
glyceraldehyde-3-phosphate dehydrogenase (human) or actin (mouse) mRNAs were quantitated using quantitative RT-PCR. Data are expressed relative to
glyceraldehyde-3-phosphate dehydrogenase and actin, respectively, and represent mean  S.E. of two experiments. C, the TILRR core is a 70 – 80-kDa protein.
Total protein was extracted from a range of cell lines, as indicated, followed by separation using SDS-PAGE (8%). Levels of TILRR were determined by Western
analysis using a TILRR-specific polyclonal antibody (1:1000) or secondary antibody alone (control), followed by horseradish peroxidase-conjugated secondary
antibody (1:5000), and visualized by ECL. Levels of -actin were similarly determined by incubating with an anti-actin antibody (1:1000) and used as a loading
control. A representative gel from one of four experiments is shown.
TILRR Potentiates IL-1RI Recruitment of MyD88
MARCH 5, 2010 • VOLUME 285 • NUMBER 10 JOURNAL OF BIOLOGICAL CHEMISTRY 7225
FIGURE 2. TILRR is a cell surface glycosylated protein, which potentiates IL-1RI activities. A, TILRR expression correlates with TIR-induced gene activity. HeLa cells
were co-transfected with pIL-8-luc (0.2 g/well (34 g/106)) and TK-RL (0.075 g/well (13 g/106)) together with TILRR cDNA (0–40 ng/well (0–7 g/106 cells)) or
empty vector (control) (left panel). Other cultures were transfected with pIL-8-luc and TK-RL, as above, together with increasing levels of TILRR siRNA, or random siRNA
(control), as indicated (right panel). Cells were incubated in the absence () or presence (f) of IL-1 (1 nM, 6 h), and luciferase activity was measured. Data are expressed
relative to levels in unstimulated cells transfected with the relevant concentrations of empty vector or random siRNA and show mean  S.E. of two experiments. *, p 
0.05; **, p 0.01. B, TILRR uniquely regulates IL-1RI function. HeLa cells were used to screen a series of receptor systems (IL-1RI, TNFR, PDGFR, TGFR) for effects of TILRR
on IL-8 promoter activity. Cells were transfected with random or TILRR-specific siRNA (100 pM) and stimulated with respective ligand at saturated levels (IL-1 (1 nM),
TNF (10 ng/ml), PDGF (25 ng/ml), TGF (3 ng/ml)). Data are expressed as percentage of activation in the presence of the relevant control (containing Random siRNA)
and demonstrate effects on IL-1RI function only. C, schematic outline of the TILRR core protein. The protein contains a GPI anchor in its C-terminal lectin domain, GAG
attachment sites (ovals), multiple N-linked glycosylation sites (hexagons), and an integrin-binding site (RGD). D and E, TILRR is localized at the cell surface. D, HeLa cells
(106 cells/10-cm dish) were plated for 48 h and then fixed (2% paraformaldehyde on ice) and stained using normal rabbit IgG (control, gray) or a TILRR specific
polyclonal antibody (white), followed by a fluorescein isothiocyanate-tagged secondary antibody, and analyzed by flow cytometry. Data show one experiment of four.
E, confocal micrograph of HeLa cells transfected with EGFP-TILRR (0.6 g/well (12 g/106 cells)). Shown is a representative micrograph demonstrating cell surface
localization of the TILRR fusion protein. Bar, 3 m.
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trast, similar screening of a series of receptor systems, including
PFGFR, TNF receptor, and TGFR, demonstrated no effects
of TILRR expression on induction of IL-8 activity (Fig. 2B).
Analysis of the 710-amino acid TILRR sequence revealed
GAG attachment sites at residues 112 and 417 and a series of
putativeN-linked glycosylation sites at residues 71, 96, 213, 392,
471, and 542. In addition, the protein contains an integrin cal-
cium-binding domain and a prominent C-terminal lectin
domain, consistent with membrane association (Fig. 2C). The
LOCtree prediction (available on theColumbiaUniversityWeb
site) gave a confidence level of 100% for extracellular localiza-
tion and identified a putative signal peptide sequence at resi-
dues 5–14. Cell surface localization of TILRRwas confirmed by
fluorescence-activated cell sorting analysis and by confocal
microscopy using an EGFP-tagged construct, which revealed a
punctuate pattern at extended processes (Fig. 2, D and E).
TILRR Controls Activation of Inflammatory Genes through
TIR Regulatory Components in a Variety of Cell Types—TILRR’s
impact at the level of IL-1RI function was confirmed using a
series of TIR domain alanine-scanningmutants.We have dem-
onstrated previously that substitutions at sites Asp369 and
Arg411 cause a 50–60% reduction in IL-1 inducedNF-B activ-
ity, whereas mutations of Tyr374 and Lys428 have no significant
effects (17). Here we show that blocking TILRR expression
caused about a 40% reduction in IL-1-induced activation
through the wild type receptor and through both of the Box 2
receptor mutants (R411A and K428A) (Fig. 3A). In contrast,
activation levels in the Box 1 receptor mutants (D369A and
Y374F) were unaffected by the TILRR siRNA, demonstrating
that substitutions in this membrane-proximal part of the TIR
domain render the receptor insensitive to TILRR expression.
TILRR signaling through the IL-1RI complex was further
supported by experiments demonstrating abrogation of the
induced amplification in the presence of DDIRAKI and
DNTRAF6 (Fig. 3B).
Assessing the effect of TILRR on a variety of cell types dem-
onstrated that blocking its expression resulted in a 50–60%
reduction in IL-1-induced activation of IL-8 in mouse macro-
phage, epithelial, and fibroblast cell lines (Fig. 3C). Similarly,
TILRR siRNA caused a nearly 70% reduction in IL-1-induced
IL-8 activity in human endothelial cells (Fig. 3D) and a 50–75%
decrease in IL-6 production by human endothelial cells and
human primary fibroblasts (Fig. 3E).
FIGURE 3. TILRR controls TIR-induced inflammatory gene activation by
IL-1 in various cell types. A, TILRR signals through Box 1 of the TIR domain.
HeLa cells were co-transfected with pIL-8-luc (34 g/106) and TK-RL (13
g/106) and wild type (WT) or TIR domain mutants of IL-1RI (22 g/106 cells),
in the presence of TILRR-specific siRNA () or random siRNA () at 100 pM,
stimulated (IL-11 nM, 6 h), and assayed for luciferase activity. Data show
effects of mutants, as described previously (17), and reduced activities
through the wild-type receptor and the Box 2 mutants in the presence of
TILRR siRNA and represent mean  S.E. of two experiments. *, p  0.05.
B, TILRR activation is controlled through IL-1RI regulatory components IRAK1
and TRAF6. Cells transfected with IL-8-luc, as above, and with DDIRAK1 (6
g/106 cells) or DNTRAF6 (6 g/106 cells), in the presence or absence of TILRR
cDNA (3 g/106 cells), as indicated, were stimulated with IL-1 (1 nM, 6 h).
Data show mean  S.E. of two experiments. **, p  0.01. C–E, TILRR controls
IL-1RI-induced gene regulation in a variety of cells. C, cells (black, Raw 264.7;
gray, C127; white, 3T3) were co-transfected with pIL-8-luc (34 g/106) and
TK-RL (13 g/106) and random- or TILRR-specific siRNA (100 pM, 1 nM), as
indicated, and stimulated with IL-1 (1 nM, 6 h), and luciferase activity was
measured. Random siRNA had no impact over a range of concentrations. Data
are expressed relative to levels in mock-transfected, unstimulated cells and
show mean  S.E. of two experiments. *, p  0.05; **, p  0.01. D, endothelial
cells were transfected with IL-8-EGFP (40 g/106 cells) and random siRNA
(100 pM) () or TILRR siRNA (100 pM) (f). Single cell images were obtained by
continuous recording during stimulation (IL-1, 1 nM), and cytoplasmic fluo-
rescence was determined at the time points indicated, using NIH Image. Data,
averaging readings from two experiments, including 30 cells, are expressed
relative to initial cytoplasmic levels, S.E.  7%, p  0.01 at 6 – 8 h. E, human
endothelial cells (HMEC-1; left) and primary gingival fibroblasts (right) were
transfected with TILRR-specific siRNA (0 pM, 100 pM, and 1 nM), as indicated,
and stimulated with IL-1 (1 nM, 6 h), and levels of IL-6 determined by an
enzyme-linked immunosorbent assay. Random siRNA had no impact over a
range of concentrations. Data show levels of protein synthesized by 106 cells
transfected with siRNA and represent mean  S.E. of two experiments per
graph. *, p  0.05; **, p  0.005.
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TILRR Controls Cell Structure and Potentiates TIR-induced
NF-B through Activation of the Ras GTPase—Effects on the
regulationofNF-Bwere confirmedbydemonstrating that block-
ing TILRR expression caused a 60% reduction in IL-1-induced
IB-phosphorylation at peak levels after 5 min of stimulation
(Fig. 4A). In addition, the presence of the TILRR siRNA caused a
decrease in inhibitor degradation from 50–60% in control cul-
tures, to 10–20%, during 60min of stimulation (Fig. 4B).
Our earlier studies showed that IL-1 stimulation causes
substrate-dependent alterations in cell shape and cytoskeletal
organization and activation of the Ras GTPase (7, 8). In addi-
tion, they revealed that these changes are induced under con-
ditions demonstrated to potentiate TILRR/IL-1RI association
and prompted analysis of TILRR involvement in mechano-
transduction (14). The experiments showed that increasing
TILRR expression causes structural alterations similar to those
induced by IL-1 stimulation, characterized by loss of extended
processes and cell rounding (Fig. 4C), and, further, that block-
ing endogenous TILRR eliminated the IL-1-induced changes in
cell morphology, demonstrating the same effects as observed in
the presence of the dominant negative N17Ras (Fig. 4C). Sub-
sequent experiments revealed a successive reduction in TILRR-
induced activation in the presence of increasing levels of
N17Ras (Fig. 4D). Further, they showed that blocking TILRR
expression caused a 75% reduction in IL-1-induced activation
in the Ras GTPase (Fig. 4E).
TILRR Function Requires Association with the Signaling
Receptor—Radioreceptor experiments demonstrated a 41  7%
reduction in IL-1 binding in the presence of TILRR siRNA (Fig.
5A). Gel electrophoresis confirmed that this corresponded to a
decrease of 58.5 4.5% in the highmolecular weight IL-1RI com-
plex, containingup to70%of the ligand,whichwasused to identify
TILRR(14) (Fig. 5B).Thepresenceof IL-1RIandTILRRwithin the
complex and its regulation by TILRR expression were confirmed
by immunoprecipitation and Western analysis, which demon-
strated reductions in the high molecular weight complex of 57 
5% in the presence of TILRR siRNA (Fig. 5C). Additional experi-
ments using a series of highmolecular weight markers confirmed
the size of the complex to be 300–350 kDa, the same size as that
determined previously (14) (data not shown).
To assess the significance of IL-1RI association in TILRR
function, residues in the extracellular domain of the signaling
receptor, selected based on their predicted effect on secondary
structure, were subjected to alanine substitution. Mutations
I41A, I69A, and N319A, while demonstrating levels of cell sur-
face expression similar to thewild type (supplemental Fig. S4A),
caused reductions of about 50–70% in the TILRR-amplified
response (Fig. 5D). In contrast, substitutions V148A, L170A,
and L295A, used as controls, had no impact (Fig. 5D). Alanine
substitution of the membrane proximal residue Asn319, pre-
dicted to affect -helical, turn, and coil regions of the protein,
had the most pronounced effects on TILRR amplification and
was used in a series of subsequent experiments. These showed
that the substitution had no impact on IL-1-induced promoter
activation in the absence ofTILRR (data not shown).Additional
analysis using cross-linking to assess the effect of the 319
mutant on IL-1RI association demonstrated a pronounced
reduction in formation of the highmolecular weight TILRR/IL-
1RI-containing complex, consistent with a link between TILRR
function and IL-1RI association (Fig. 5E).
TILRR Association with IL-1RI Enhances Inflammatory Gene
Regulation by Potentiating MyD88 Recruitment and MyD88-
dependent Activation of NF-B—Further analyses were carried
out using a series of TILRR mutants. These demonstrated that
alanine substitution of the predicted glycosaminoglycan bind-
ing site at residue 112 caused a 50% reduction in IL-1-induced
promoter activation in the presence of TILRR, consistentwith a
role for the fibronectin heparin-binding region in TILRR func-
tion (supplemental Fig. S2) (14). Further, introducing alanine
substitutions of residues within the TILRR core protein,
selected based on their predicted impact on the secondary
structure, identified three mutations (D58A, D448A, and
Q558A), which, while demonstrating the same level of cell sur-
face expression as the wild type receptor (supplemental Fig.
S4B), resulted in a 30–60% reduction in IL-1-induced activa-
tion (Fig. 6A). In comparison, substitutions of residues His82,
Asp119, His480, andAsp534, used as controls, causednomore than
a 10%decrease in activity. Parallel experiments demonstrated that
substitution of themembrane-proximal residue Asp448, with pre-
dicted effects on -helical, turn, and coil regions of the protein,
significantly reduced formation of the TILRR-containing IL-1RI
complex, in agreementwith a relevanceof signaling receptor asso-
ciation to TILRR function (Fig. 6B).
FIGURE 4. TILRR controls cell structure and activates the Ras GTPase to potentiate IL-1RI-induced NF-B. A, TILRR controls IL-1-induced IB phosphor-
ylation. HeLa cells were transfected with random (f) or TILRR siRNA (Œ) (100 pM) and stimulated (IL-1, 1 nM) for the times indicated and analyzed by Western
blotting, using a phosphospecific anti-IB antibody or anti--actin (loading control). Data are expressed relative to levels in unstimulated samples for each
condition and represent mean  S.E. of two experiments, p  0.05 at the 5 min peak. B, TILRR controls IL-1-induced IB degradation. Confocal micrographs
of HeLa cells were transfected with IB-EGFP (17 g/106 cells) alone or in the presence of random or TILRR-specific siRNA (100 pM) and stimulated with IL-1
(1 nM). Quantitation, using NIH Image or Image J, shows levels of IB-EGFP cytoplasmic fluorescence in the presence of TILRR siRNA (f) or in the absence of
siRNA () indistinguishable from those measured in the presence of random siRNA. Data are from three experiments, including 55 cells, S.E.  10 –25%, p 
0.05 at 60 min. Bar, 10 m. C, IL-1-induced changes in cell structure are controlled by TILRR. Cells were transfected with TILRR cDNA, siRNA, or the dominant
negative N17Ras and incubated with medium alone or IL-1 (1 nM, 1 h), as indicated. Following fixation, actin filaments were stained using rhodamine-tagged
phalloidin, and samples were analyzed by confocal microscopy. The experiments demonstrate that in unstimulated cells (panels 1–3) TILRR cDNA causes
pronounced cell rounding with reductions in cell size and extended processes (arrows, compare panels 1 and 2), whereas cells transfected with the dominant
negative N17Ras have an appearance similar to that of mock-transfected cells (arrows, compare panels 1 and 3). Further, the data show that these changes
(arrows) are induced by IL-1 (compare panels 1 and 4) but do not occur during stimulation in the presence of TILRR siRNA or N17Ras, where cells demonstrate
an appearance similar to that observed in unstimulated mock-transfected cultures (compare panels 5 and 6 with panel 1). Bar, 2 m. D, TILRR amplification is
regulated through the Ras GTPase. Cells were co-transfected with pIL-8-luc (34 g/106 cells) and TK-RL (13 g/106 cells) alone () or together with TILRR cDNA
() (4 g/106 cells) and increasing levels of N17Ras, as indicated, and incubated in medium alone or stimulated with IL-1 (1 nM, 6 h). Data are expressed relative
to activity in mock-transfected, unstimulated samples and represent mean  S.E. of two experiments. *, p  0.05; **, p  0.01. E, TILRR controls IL-1RI-induced
Ras activation. Cells were plated on fibronectin, transfected with random () or TILRR-specific (f) siRNA (100 pM), and stimulated with IL-1 (1 nM) for various
times, as indicated. Immunoprecipitated active Ras was detected by Western blot and quantitated by NIH Image, and data were expressed relative to levels in
unstimulated cultures, using actin as the loading control, and represent Mean  S.E. of two experiments, p  0.05 at 2.5 min.
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Subsequent experiments to assess the impact of TILRR asso-
ciation on adapter protein usage showed that a dominant neg-
ative MyD88 caused a concentration-dependent reduction in
IL-1-induced activation in the presence of the TILRR cDNA,
with total abrogation at high enough levels (Fig. 6C). Impacts on
adapter protein recruitment were assessed byWestern analysis
followingmembrane permeable cross-linking and immunopre-
cipitation (Fig. 6D). This showed that enhancingTILRR expres-
sion to levels demonstrated to induce formation of the high
molecular weight IL-1RI complex potentiated TIR association
of MyD88 by 4-fold, resulting from a 2-fold enhancement of
IL-1 receptor levels (see Fig. 5,A–C) and a 2-fold increase in the
MyD88/IL-1RI-ratio (Fig. 6D).
The data show that TILRR, a cell surface proteoglycan, asso-
ciates with IL-1RI to potentiate NF-B activation and inflam-
matory responses by increasing ligand binding and receptor
expression and, further, that signal amplification is due to
enhanced recruitment of the MyD88 adapter to the signaling
receptor complex and to coordination of activities through the
IL-1RI TIR domain and associated regulatory components with
induction of the Ras GTPase (Fig. 7).
DISCUSSION
We report on a novel IL-1RI co-receptor, TILRR, which associ-
ateswith the signaling receptor complex topotentiate recruitment
of the MyD88 adapter, control induction of the Ras GTPase, and
amplify activation of NF-B and inflammatory genes.
Earlier studies identified TILRR as a heparan sulfate proteo-
glycan, recruited to the IL-1 receptor complex at focal adhe-
sions (14). Involvement of TILRR in structural control is con-
sistent with its role in induction of substrate-dependent
alterations in cell shape and in activation of the Ras GTPase
through IL-1RI (7, 8). The results thus demonstrate a link
between TILRR expression and induction of Ras activity and
amplification of NF-B and suggest that TILRR functions as a
coordinator of IL-1-induced responses and mechanotransduc-
tion (22). This is further supported by its homology with mem-
bers of the FRAS1 family and indicates a role for TILRR in
regulation of inflammatory control in the context of tissue
structure and development (21). Its recruitment to the receptor
complex may thus regulate IL-1RI function and cellular re-
sponses in a topographical and time-dependent manner (23).
A role for TILRR in ligand binding is consistent with its lack
of effect on unstimulated levels. Further, it is supported by the
reduced effect of TILRR on IL-1 responses, following substitu-
tions at residues 39 and 66, within the IL-1R ligand-binding
domain (24). It is also consistent with the reduction in binding
affinity (Ka) and increase in downstream activation caused by
TILRR/IL-1RI association, characteristic of cell surface glyco-
protein and proteoglycan co-receptors (14, 25, 26). TILRRmay
thus have a role similar to that of -glycan and gp130, which
FIGURE 5. TILRR controls IL-1RI function by increasing ligand binding and
receptor complex levels. A, TILRR expression controls ligand binding. HeLa
cells were plated on fibronectin and transfected with random (ƒ) or TILRR
siRNA (100 pM) (Œ). Specific cell surface receptor binding was determined by
incubating with radiolabeled 125I-IL-1 (2 h, 4 °C) at the concentrations indi-
cated (S.E.  7%). B, TILRR expression controls formation of a 300 –350-kDa
IL-1RI complex. HeLa cells, plated on fibronectin and transfected with TILRR
siRNA or random siRNA (100 pM) as in (A), were incubated with 125I-IL-1 (1 nM,
2 h, 4 °C) and cross-linked using bis(sulfosuccinimidyl)suberate, and extracts
were analyzed by SDS-PAGE (8%). One experiment of three is shown (S.E. 
7%). C, TILRR and IL-1RI associate to form a 300 –350-kDa complex. HeLa cells
transfected with empty vector (Mock) or TILRR cDNA (10 g/106 cells) or TILRR
siRNA (100 pM) and incubated (IL-1, 1 nM) as in A and B, were cross-linked and
immunoprecipitated with an anti-IL-1RI antibody (2 g/ml) and analyzed by
SDS-PAGE (4 –12%). Levels of TILRR and IL-1RI were determined by Western
blotting, using IgG as the loading control. One representative gel is shown. D,
TILRR control of IL-1RI function is dependent on the structure of the signaling
receptor extracellular domain. Cells were co-transfected with pIL-8-luc (34
g/106 cells), TK-RL (13 g/106 cells), wild type TILRR (3.6 g/106 cells), and
wild type or mutant IL-1RI (22 g/106 cells), as indicated, and stimulated with
IL-1 (1 nM, 6 h), and extracts were assayed for luciferase activity. Data are
expressed relative to activation in mock-transfected, IL-1-stimulated samples
and represent mean  S.E. of two experiments. *, p  0.01; **, p  0.001.
E, TILRR function is dependent on association with IL-1RI. Cells were trans-
fected with a mock construct or wild type TILRR (10 g/106 cells) together
with wild type IL-1RI (WT) or the N319A IL-1RI mutant (10 g/106 cells), as
indicated, and incubated with 125I-IL-1 (1 nM, 2 h, 4 °C), and cross-linked
extracts were analyzed by SDS-PAGE. Quantitation of levels of the high
molecular weight complex was carried out using scanned autoradiograms
and NIH Image, and data are expressed relative to levels of the 97 kDa band
(IL-1RI  ligand) and represent mean  S.E. of two experiments. **, p  0.01.
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present ligand to their respective system signaling receptors
(27, 28). In addition, the increase in cell surface binding may be
a consequence of the enhanced receptor expression and caused
by a reduced rate of internalization, due to retention of IL-1RI
at focal adhesions, following TILRR association (14).
Effects on receptor function are expected to derive from alter-
ations in receptor complexcompositionandconformation follow-
ing TILRR association. With up to 70% of the receptor-bound
ligand present within the highmolecular weight, TILRR-contain-
ing complex, such changes are likely to have significant conse-
quences for receptor dimerization, signal amplification, and
downstream control (4, 14). Detailed analysis of effects of TILRR
FIGURE 6. TILRR controls MyD88-dependent signaling and MyD88 asso-
ciation. A, TILRR function is dependent on the structure of its core protein.
HeLa cells were co-transfected with wild type (WT) or mutant TILRR (3.6
g/106 cells), together with pIL-8-luc (34 g/106 cells) and TK-RL (13 g/106
cells), and stimulated with IL-1 (1 nM, 6 h), and luciferase activity was mea-
sured. Data are expressed relative to activity in mock-transfected cells and
represent mean  S.E. of two experiments. *, p  0.05; **, p  0.001. B, func-
tionally impaired TILRR mutants do not associate with IL-1RI. HeLa cells were
transfected with empty vector (Mock) or wild type TILRR or D448 TILRR (10
g/106 cells), as indicated, and incubated with 125I-IL-1 (1 nM, 2 h, 4 °C) and
cross-linked bis(sulfosuccinimidyl)suberate, and extracts were analyzed by
SDS-PAGE. Quantitation of scanned autoradiograms by NIH Image shows lev-
els of the high molecular weight, TILRR-containing complex, expressed rela-
tive to levels of the 97 kDa band (IL-1 RI  ligand) and represent mean  S.E.
of two experiments. *, p  0.05. C, TILRR amplification of IL-1RI responses is
MyD88-dependent. HeLa cells were co-transfected with pIL-8-luc (34 g/106
cells) and TK-RL (13 g/106 cells) in the presence of TILRR cDNA (11 g/106
cells) or the relevant mock construct and increasing concentrations of DN
MyD88, as indicated, stimulated with IL-1 (1 nM, 6 h), and assayed for lucifer-
ase activity. Data are expressed relative to activity in mock-transfected,
unstimulated cells and represent mean  S.E. of two experiments. *, p  0.01;
**, p  0.001. D, TILRR increases association of MyD88 with IL-1RI. HeLa cells
transfected with empty vector (Mock) or TILRR cDNA (TILRR, 10 g/106cells) were
stimulated with IL-1 (1 nM) for 0 () or 20 () min, as indicated, subjected to
membrane-permeable cross-linking (DSS), immunoprecipitated using an IL-1RI
antibody (2 g/ml), and analyzed by SDS-PAGE (4–12%). Levels of MyD88 and
IL-1RI were determined by Western blotting, using IgG as the loading control.
One representative gel is shown. Quantitation was done using NIH Image, and
data are expressed as levels of MyD88 relative to IL-1RI for each condition and
represent mean  S.E. of two experiments. *, p  0.05; **, p  0.001.
FIGURE 7. TILRR enhances MyD88 recruitment to IL-1RI to coordinate TIR-
and Ras-dependent activation. TILRR association with IL-1RI increases
ligand binding and receptor complex formation and potentiates recruitment
of the MyD88 adapter to the TIR domain to increase signal amplification at the
level of the receptor complex and associated regulatory components and to
direct activation of the Ras GTPase and magnify induction of NF-B and
inflammatory genes.
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association on complex composition and on association of regula-
tory componentswill be carriedout in future studies using crystal-
lography, incombinationwith surfaceplasmonresonanceandsat-
uration transfer difference NMR.
Sequential changes in signaling receptor conformation follow-
ing TILRR association are likely to underlie the enhanced recruit-
ment of theMyD88adapter and the increased signal amplification
(4). In addition, such changesmay facilitate downstream signaling
cross-talkand linkTIR-inducedactivationwithsubstrate-depend-
ent control and structural regulation through the GTPases (29,
30). This is consistent with the requirement of TILRR in IL-1-
induced activation of the Ras GTPase and suggests that the
TILRRIL-1RI complex may constitute a platform for controlling
structurally sensitive inflammatory responses by coordinating
IL-1-regulated activities with mechanotransduction (31, 32).
A link between structural regulation at the level of signaling
cross-talkand the increase inMyD88-dependentactivation is con-
sistent with the observed changes in the actin cytoskeleton. Our
earlier studies have demonstrated that such Ras-controlled
changes in cytoskeletal organization, induced by IL-1, involve
phosphorylation of the transmembrane linkage protein talin and
alterations at focal adhesions (7, 8). This type of effect on substrate
interactions and actin reorganization by cytokines such as TNF
has been demonstrated to be adapter-controlled and fundamental
in the regulation of biological responses and cell behavior during
development and wound healing (33–35). In addition, alterations
in cell shape and the actin cytoskeleton will provide an efficient
system for controllingNF-B at the level of the IBNF-B com-
plex, byallowing rapidchanges in theavailablepoolof IBduring
activation (36). Future studies will determine the significance of
TILRR in the kinetics of complex dissociation, specifically in rela-
tion to overall network control and gene induction profiles.
We here identify a substrate-dependent and structurally reg-
ulated IL-1RI co-receptor, TILRR, which associates with the
signaling receptor to potentiate activation of NF-B. We dem-
onstrate that TILRR association and ensuing changes in recep-
tor complex composition potentiate ligand binding and recruit-
ment of MyD88 and identify a role for TILRR in control of the
Ras-GTPase and cytoskeletal organization.
We conclude that TILRR controls amplification of inflam-
matory responses by linking TIR-induced activities withmech-
anotransduction and expect it to be relevant to a range of
diseases characterized by dysregulation of inflammatory re-
sponses. Future studies will focus on the role of TILRR in sig-
naling cross-talk and in regulation of gene activation profiles
under physiological and pathological conditions.
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